Skip to main content
SpringerLink
Log in

Decongestant Activity of Desloratadine in Controlled-Allergen-Exposure Trials

  • Original Research Article
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

Nasal obstruction, which many patients consider to be the most bothersome symptom of seasonal allergic rhinitis (SAR), is generally refractory to oral anti-histamine therapy. Effective resolution of nasal obstruction associated with SAR may help to prevent lower-airway disorders and other adverse sequelae (e.g. otitis media with effusion). Desloratadine, a nonsedating antihistamine with marked inhibitory effects on the early- and late-phase allergic responses, affords significant relief of sneezing, pruritus and rhinorrhoea, as well as nasal congestion. Using the Vienna Challenge Chamber, a closed system that enables rigorously controlled allergen exposure, we observed that a single 5mg dose of desloratadine rapidly and markedly reduced postexposure nasal obstruction in a pilot study. Separately, three randomised, double-blind, placebo-controlled trials demonstrated that desloratadine significantly reduced nasal blockage, as well as acute SAR symptoms, from baseline as compared with placebo over a 5-hour interval in the pollen chamber. The favourable effects of desloratadine on early-phase symptoms were consistent with evidence from controlled-allergen-exposure trials involving other antihistamines (cetirizine, fexofenadine). However, desloratadine also significantly protected against allergen-induced declines in nasal airflow (as assessed by active anterior rhinomanometry) and reduced nasal secretion weights compared with placebo in a controlled-allergen-exposure paradigm. The consistent decongestant effects of desloratadine in pollen-chamber trials were also concordant with data from clinical trials conducted under natural, ambient exposure conditions. Taken together, these findings support the clinical utility of desloratadine, a nonsedating, long-acting, high-affinity H1 receptor antagonist with decongestant properties.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Table I
Table II
Table III

Similar content being viewed by others

References

  1. Parikh A, Scadding GK. Seasonal allergic rhinitis. BMJ 1997; 314(7091): 1392–5

    Article  PubMed  CAS  Google Scholar 

  2. Sibbald B, Rink E. Epidemiology of seasonal and perennial rhinitis: clinical presentation and medical history. Thorax 1991; 46(12): 895–901

    Article  PubMed  CAS  Google Scholar 

  3. Young T, Finn L, Kim H. Nasal obstruction as a risk factor for sleep-disordered breathing. The University of Wisconsin Sleep and Respiratory Research Group. J Allergy Clin Immunol 1997; 99(2): S757–62

    Article  PubMed  CAS  Google Scholar 

  4. Spector SL. Overview of comorbid associations of allergic rhinitis. J Allergy Clin Immunol 1997; 99(2): S773–80

    Article  PubMed  CAS  Google Scholar 

  5. Fireman P. Otitis media and eustachian tube dysfunction: connection to allergic rhinitis. J Allergy Clin Immunol 1997; 99(2): S787–97

    Article  PubMed  CAS  Google Scholar 

  6. Griffin MP, McFadden ER, Ingram RH. Airway cooling in asthmatic and nonasthmatic subjects during nasal and oral breathing. J Allergy Clin Immunol 1982; 69(4): 354–9

    Article  PubMed  CAS  Google Scholar 

  7. Kirkpatrick MB, Sheppard D, Nadel JA, et al. Effect of the oronasal breathing route on the bronchoconstrictor response to sulfur dioxide in exercising asthmatic subjects. Am Rev Respir Dis 1982; 125: 627–31

    PubMed  CAS  Google Scholar 

  8. Corren J. Allergic rhinitis and asthma: how important is the link? J Allergy Clin Immunol 1997; 99(2): S781–6

    Article  PubMed  CAS  Google Scholar 

  9. Horak F, Stübner UP, Zieglmayer R, et al. Onset and duration of action of desloratadine after controlled pollen challenges in patients with seasonal allergic rhinitis [abstract]. Allergy 2000; 55 Suppl. 63: 279

    Google Scholar 

  10. Horak F, Stübner UP, Zieglmayer R, et al. Decongestant activity of desloratadine versus placebo in allergic rhinitis: results from three single-dose, placebo-controlled, allergen chamber trials [abstract]. Allergy 2001; 56 Suppl. 68: 79

    Google Scholar 

  11. Cartier A, Bernstein IL, Burge PS, et al. Guidelines for bronchoprovocation on the investigation of occupational asthma. Report of the Subcommittee on Bronchoprovocation for Occupational Asthma. J Allergy Clin Immunol 1989; 84(5 Pt 2): 823–9

    Article  PubMed  CAS  Google Scholar 

  12. Bousquet J, Van Cauwenberge P, Khaltaev N (for the WHO) in collaboration with the World Health Organization. Allergic rhinitis and its impact on asthma. ARIA workshop report. 7: diagnosis and management. J Allergy Clin Immunol 2001; 108 Suppl. 5: S208–19

    Google Scholar 

  13. Craig TJ, Teets S, Lehman EB, et al. Nasal congestion secondary to allergic rhinitis as a cause of sleep disturbance and daytime fatigue and the response to topical nasal corticosteroids. J Allergy Clin Immunol 1998; 101: 633–7

    Article  PubMed  CAS  Google Scholar 

  14. Day JH, Briscoe MP, Welsh A, et al. Onset of action, efficacy, and safety of a single dose of fexofenadine hydrochloride for ragweed allergy using an environmental exposure unit. Ann Allergy Asthma Immunol 1997; 79(6): 533–40

    Article  PubMed  CAS  Google Scholar 

  15. Horak F, Stübner P, Zieglmayer R, et al. Controlled comparison of the efficacy and safety of cetirizine 10 mg o.d. and fexofenadine 120 mg o.d. in reducing symptoms of seasonal allergic rhinitis. Int Arch Allergy Immunol 2001; 125(1): 73–9

    Article  PubMed  CAS  Google Scholar 

  16. Day JH, Briscoe M, Widlitz MD. Cetirizine, loratadine, or placebo in subjects with seasonal allergic rhinitis: effects after controlled ragweed pollen challenge in an environmental exposure unit. J Allergy Clin Immunol 1998; 101(5): 638–45

    Article  PubMed  CAS  Google Scholar 

  17. Meltzer EO, the Desloratadine Study Group. Rapid onset of action of desloratadine in patients with seasonal allergic rhinitis [abstract 527]. J Allergy Clin Immunol 2001; 107: S160

    Article  Google Scholar 

  18. Shapiro G, the Desloratadine Study Group. Decongestant effects of desloratadine in patients with seasonal allergic rhinitis and asthma [abstract 530]. J Allergy Clin Immunol 2001; 107: S161

    Google Scholar 

  19. Horak F, Jager S, Toth J, et al. Efficacy and tolerability of astemizole-D and loratadine-D during prolonged, controlled allergen challenge in the Vienna Challenge Chamber. Arzneimittelforschung 1996; 46(11): 1077–81

    PubMed  CAS  Google Scholar 

  20. Horak F, Toth J, Marks B, et al. Efficacy and safety relative to placebo of an oral formulation of cetirizine and sustained-release pseudoephedrine in the management of nasal congestion. Allergy 1998; 53(9): 849–56

    Article  PubMed  CAS  Google Scholar 

  21. Corren J, Harris AG, Aaronson D, et al. Efficacy and safety of loratadine plus pseudoephedrine in patients with seasonal allergic rhinitis and mild asthma. J Allergy Clin Immunol 1997; 100(6 Pt 1): 781–8

    Article  PubMed  CAS  Google Scholar 

  22. Lorber R, Danzig M, the DL-D12 Study Group. Desloratadine and pseudoephedrine provide similar relief of nasal congestion in patients with seasonal allergic rhinitis [poster]. Presented at the XXth Congress of the European Academy of Allergology and Clinical Immunology; 2001 May 9–13; Berlin

  23. Horak F, Stübner P, Zieglmayer R, et al. Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen induced allergic rhinitis in an allergen exposure unit. J Allergy Clin Immunol 2002; 109: 956–61

    Article  PubMed  CAS  Google Scholar 

  24. Settipane RA. Complications of allergic rhinitis. Allergy Asthma Proc 1999; 20(4): 209–13

    Article  PubMed  CAS  Google Scholar 

  25. Henriksen JM, Wenzel A. Effect of an intranasally administered corticosteroid (budesonide) on nasal obstruction, mouth breathing, and asthma. Am Rev Respir Dis 1984; 130(6): 1014–8

    PubMed  CAS  Google Scholar 

  26. Marks MB. Allergy in relation to orofacial dental deformities in children: a review. J Allergy 1965; 36: 293–302

    Article  PubMed  CAS  Google Scholar 

  27. Proctor DF. The upper airways: I. nasal physiology and defense of the lungs. Am Rev Respir Dis 1977; 115: 97–129

    PubMed  CAS  Google Scholar 

  28. Lipworth BJ, Jackson CM. Safety of inhaled and intranasal corticosteroids: lessons for the new millennium. Drug Saf 2000; 23(1): 11–33

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Funding for these studies was provided by Essex Pharma GmbH (Schering-Plough Pharmaceuticals).

Author information

Authors and Affiliations

  1. HNO-Klinik AKH, ENT Clinic, University of Vienna, Währinger Gürtel 18-20 Wien, Vienna, A-1090, Austria

    Friedrich Horak & Petra Stübner

Authors
  1. Friedrich Horak
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Petra Stübner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Friedrich Horak.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Horak, F., Stübner, P. Decongestant Activity of Desloratadine in Controlled-Allergen-Exposure Trials. Clin. Drug Investig. 22 (Suppl 2), 13–20 (2002). https://doi.org/10.2165/00044011-200222002-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00044011-200222002-00002

Keywords

Search

Navigation